Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filip Machaj

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Expert Opinion on Drug Discovery|October 31, 2019
The evolution in our understanding of the genetics of rheumatoid arthritis and the impact on novel drug discoveryFilip Machaj, Jakub Rosik, Bartosz Szostak, et al.
Expert Review of Hematology|October 15, 2019
Umbilical cord blood transplantation and the impact of the CTLA4 genotype on outcomesBartosz Szostak, Filip Machaj, Jakub Rosik, et al.
Expert Opinion on Investigational Drugs|December 23, 2018
CTLA4 antagonists in phase I and phase II clinical trials, current status  and  future perspectives for cancer therapyBartosz Szostak, Filip Machaj, Jakub Rosik, et al.
International Journal of Molecular Sciences|April 3, 2021
The Role of CTLA4 and Its Polymorphisms in Solid Organ and Haematopoietic Stem Cell TransplantationJakub Rosik, Bartosz Szostak, Filip Machaj, et al.
Expert Opinion on Drug Metabolism & Toxicology|June 6, 2020
Using pharmacogenetics to predict methotrexate response in rheumatoid arthritis patientsBartosz Szostak, Filip Machaj, Jakub Rosik, et al.
Annals of Human Genetics|October 2, 2019
The role of genetics and epigenetics in the pathogenesis of gestational diabetes mellitusJakub Rosik, Bartosz Szostak, Filip Machaj, et al.
Expert Opinion on Therapeutic Targets|August 21, 2018
Potential targets of gene therapy in the treatment of heart failureJakub Rosik, Bartosz Szostak, Filip Machaj, et al.
Therapeutics and Clinical Risk Management|February 19, 2019
New therapies for the treatment of heart failure: a summary of recent accomplishmentsFilip Machaj, Elżbieta Dembowska, Jakub Rosik, et al.
International Journal of Molecular Sciences|October 29, 2025
microRNAs as Biomarkers and Therapeutic Targets in Rheumatoid ArthritisFilip Machaj, Magdalena Chmielewska-Jeznach, Anna Koryszewska-Bagińska, et al.
Expert Opinion on Therapeutic Targets|July 21, 2023
Improving mitochondrial function in preclinical models of heart failure: therapeutic targets for future clinical therapies?Anna Gorący, Jakub Rosik, Joanna Szostak, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Expert Opinion on Drug Discovery|October 31, 2019
The evolution in our understanding of the genetics of rheumatoid arthritis and the impact on novel drug discoveryFilip Machaj, Jakub Rosik, Bartosz Szostak, et al.
Expert Review of Hematology|October 15, 2019
Umbilical cord blood transplantation and the impact of the CTLA4 genotype on outcomesBartosz Szostak, Filip Machaj, Jakub Rosik, et al.
Expert Opinion on Investigational Drugs|December 23, 2018
CTLA4 antagonists in phase I and phase II clinical trials, current status  and  future perspectives for cancer therapyBartosz Szostak, Filip Machaj, Jakub Rosik, et al.
International Journal of Molecular Sciences|April 3, 2021
The Role of CTLA4 and Its Polymorphisms in Solid Organ and Haematopoietic Stem Cell TransplantationJakub Rosik, Bartosz Szostak, Filip Machaj, et al.
Expert Opinion on Drug Metabolism & Toxicology|June 6, 2020
Using pharmacogenetics to predict methotrexate response in rheumatoid arthritis patientsBartosz Szostak, Filip Machaj, Jakub Rosik, et al.
Annals of Human Genetics|October 2, 2019
The role of genetics and epigenetics in the pathogenesis of gestational diabetes mellitusJakub Rosik, Bartosz Szostak, Filip Machaj, et al.
Expert Opinion on Therapeutic Targets|August 21, 2018
Potential targets of gene therapy in the treatment of heart failureJakub Rosik, Bartosz Szostak, Filip Machaj, et al.
Therapeutics and Clinical Risk Management|February 19, 2019
New therapies for the treatment of heart failure: a summary of recent accomplishmentsFilip Machaj, Elżbieta Dembowska, Jakub Rosik, et al.
International Journal of Molecular Sciences|October 29, 2025
microRNAs as Biomarkers and Therapeutic Targets in Rheumatoid ArthritisFilip Machaj, Magdalena Chmielewska-Jeznach, Anna Koryszewska-Bagińska, et al.
Expert Opinion on Therapeutic Targets|July 21, 2023
Improving mitochondrial function in preclinical models of heart failure: therapeutic targets for future clinical therapies?Anna Gorący, Jakub Rosik, Joanna Szostak, et al.
Pageof 3